Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. RESULTS: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. CONCLUSIONS: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Overview
CoChat Summary
TL;DR
In a phase 3 U.S. trial, mRNA-1273 (100 μg given as two doses 28 days apart) prevented symptomatic Covid-19 with 94.1% efficacy and showed no safety concerns beyond transient reactogenicity. Severe Covid-19 occurred in 30 participants, all in the placebo group.
Key findings
- Among 30,420 randomized participants (15,210 per group), the primary per-protocol analysis found symptomatic Covid-19 in 11 mRNA-1273 recipients vs. 185 placebo recipients (3.3 vs. 56.5 per 1000 person-years), for vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001).
- Severe Covid-19 occurred in 30 participants, all in the placebo group (vaccine efficacy 100%; 95% CI could not be estimated to 1.0), including one Covid-19–related death.
- Solicited local adverse events were more frequent with mRNA-1273 after dose 1 (84.2% vs. 19.8%) and dose 2 (88.6% vs. 18.8%); solicited systemic events were also more frequent after dose 1 (54.9% vs. 42.2%) and dose 2 (79.4% vs. 36.5%). Serious adverse events were similar (0.6% in both groups).
- Efficacy was similar across subgroups, including 95.6% among participants 18 to <65 years, 86.4% among those ≥65 years, and 97.5% in communities of color.
Methods
- Phase 3 randomized, observer-blinded, placebo-controlled trial conducted at 99 U.S. centers; adults at high risk for SARS-CoV-2 infection or severe Covid-19 were assigned 1:1 to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.
- The primary end point was prevention of symptomatic Covid-19 with onset at least 14 days after the second injection in per-protocol participants who were seronegative at baseline; cases were adjudicated, and vaccine efficacy was defined as 1 minus the hazard ratio (mRNA-1273 vs. placebo) using a stratified Cox proportional hazards model.
- Safety was assessed in all participants who received at least one injection, including solicited local and systemic adverse events for 7 days after each injection, unsolicited adverse events for 28 days, and serious/medically attended events through day 759.
Limitations
- Stated: short duration of safety and efficacy follow-up (median 64 days after the second dose; 2-year follow-up planned); no identified correlate of protection; insufficient data to assess asymptomatic infection; limited cases in older adults, racial/ethnic minorities, and previously infected persons; pregnant women and children were excluded.
- Stated: the trial was not designed to evaluate single-dose efficacy; rare adverse events are hard to detect given sample size; long-term risk of enhanced respiratory disease after exposure remains unknown.
- Evident: the primary analysis reflects only short-term follow-up, so durability of protection is unknown; subgroup estimates have wide confidence intervals (e.g., ≥65 years: 86.4%, 95% CI 61.4 to 95.2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 3 Not checked · 79 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The efficacy of mRNA-1273 is in line with that of the recently reported BNT162b2 mRNA vaccine. 16”
What the sources say
- Supportedcites [16] 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. source
The Abstract Results report that BNT162b2 was 95% effective in preventing Covid-19, and the Discussion likewise describes 95% efficacy after two doses. The comparison with mRNA-1273 is the citing authors’ own framing; this source supplies the BNT162b2 efficacy result. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. 1,4”
What the sources say
- Supportedcites [1] 1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-31. source
The Methods identify this as a phase 1 trial of mRNA-1273 that evaluated reactogenicity. The Results (Vaccine Safety; page unavailable) report its reactogenicity findings, so it supports the citation’s reference to previously reported phase 1 data. (LLM, conf=0.88)
- Supportedcites [4] 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38. source
The Discussion states that the authors observed no systematic differences in reactogenicity between the older participants in this study and younger mRNA-1273 recipients reported previously. It cautions that the small groups do not permit meaningful formal statistical comparisons, but the citing sentence makes only a qualitative comparison. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the overall population, the incidence of treatment-related severe adverse events was higher in the mRNA-1273 group (71 participants [0.5%]) than in the placebo group (28 participants [0.2%]) (Tables S8 and S15).”
plainstates an associationn = 71- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were deemed by the trial team to be related to the vaccine or placebo were reported among 4.5% of participants in the placebo group and 8.2% in the mRNA-1273 group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative incidence of these adverse events according to vaccine group was not affected by age.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 88 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently licensed vaccines have shown efficacies of up to 95% in preventing laboratory-confirmed infection over the first few months after vaccination61–63”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
43 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Self-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationDeveloping Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Cited by
Items 10,601–10,700 of 10,906
Mundae, R. S., Wagley, S., Ryan, E. H., Parke, D. W., Mittra, R. A., & Tang, P. H. (2022) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2022.05.013
A review of the most influential research papers on COVID-19: An excerpt with comments and insights
Sinha, S., Modak, N. M., & Sana, S. S. (2024) · Yugoslav journal of operations research · doi:10.2298/yjor231215006s
Kasamatsu, A., Ohfuji, S., Suita, A., Kondo, K., Nakata, H., Kita, T., Deguchi, A., Fujimoto, M., Iba, K., Sakamoto, H., et al. (2025) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.70028
Review of Immunologic Manifestations of COVID-19 Infection and Vaccination
Pozdnyakova, V., Weber, B., Cheng, S. C., & Ebinger, J. E. (2023) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.08.006 · Cited by 1
Hayashi, R., Takami, Y., Fujigaki, H., Amano, K., Akita, K., Yamana, K., Maekawa, A., Saito, K., & Takagi, Y. (2024) · The International Journal of Artificial Organs · doi:10.1177/03913988241234475
Longitudinal functional lung imaging in children with Post-COVID-19 syndrome
Kraus, C., Tan, L., Hinsen, M., Schmidt, S., Nedoschill, E., Wachter, F., Mandelbaum, H., Wagner, A. L., Schöffl, I., Weigelt, A., et al. (2026) · Molecular and Cellular Pediatrics · doi:10.1186/s40348-025-00216-x
“The introduction of vaccines in late 2020 led to a reduction in overall mortality and patients requiring intensive care [2, 3], shifting the focus toward the long-term sequelae of the infection [4, 5].”
Vaccine Mandates: A Lesson in Technocracy and Populism
Matthews, S., & Doolittle, B. R. (2025) · Journal of Bioethical Inquiry · doi:10.1007/s11673-025-10490-z
Levine, K. S., Blanc, R., Wang, Q., Malca, H., Sekulovich, R. E., Jin, H., Liu, S. N., Verhoeven, C., Sullivan, B. M., Smolenov, I. V., et al. (2026) · The Journal of Immunology · doi:10.1093/jimmun/vkag141.1295
Infectious, Immune-Mediated, and Vaccine-Associated Ocular Adverse Events
Rojas, R., & Hinkle, D. M. (2025) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1177/10807683251363420
Managing two waves of the COVID-19 pandemic in northern emergency departments in Paris: COVIDORG II
Minka, F. H., Minka, S. O., Revue, E., Chauvin, A., Casalino, E., Plaisance, P. I., & Choquet, C. (2022) · Journal Européen des Urgences et de Réanimation · doi:10.1016/j.jeurea.2022.08.004
A Simple Method to Evaluate the Length of Poly(A) Tails in mRNA
Mumenthaler, J., Feldmann, M., Mamaghani, S., Penna, R. R., Frei, J., Jarzebska, N., Mellett, M., Guenova, E., Kündig, T. M., Läuchli, S., et al. (2026) · Methods and Protocols · doi:10.3390/mps9040109
“The synthesis of mRNA, such as that used in approved vaccines against SARS-CoV2 [1–3] or Respiratory Syncytial Virus (RSV) [4], as well as in many new drugs currently under development [5,6], is achieved by in vitro transcription (ivt) of a DNA template [7], initially using purified RNA polymerase…”
Ali, M. T., Chapra, A. F., Mohamed, S., Ghareeb, A. N., Kuwari, M. A., Karim, S. A., Hamid, T., Hassan, E. A. A., Qahtani, A. A., Asaad, N., et al. (2024) · Heart Views · doi:10.4103/heartviews.heartviews_62_24
New-Onset Graves’ Disease and Type 1 Diabetes After COVID-19 and Anti-SARS-CoV-2 Vaccination
di Filippo, L., Terenzi, U., Menotti, S., Santoro, S., Doga, M., & Giustina, A. (2025) · Springer eBooks · doi:10.1007/978-3-032-01700-0_6
de Lima, V. A., Ferreira, R. D. S., Oliva, M. L. V., Andreata‐Santos, R., Janini, L. M., Maricato, J. T., Akamatsu, M. A., Ho, P. L., & Schenkman, S. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.15.528632
He, X. (2026) · Springer eBooks · doi:10.1007/978-981-95-9598-3_16
Lee, D. W., Avena, L. E., Berrueta, D. M., Koch, M., Choi, A., Oestreicher, J., Hillebrand, W., Zhou, H., Pajón, R., Carfí, A., et al. (2022) · medRxiv · doi:10.1101/2022.01.28.21268247
Self-citationAdzavon, K. P., Zhao, W., & Sheng, W. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.127405
Ahmed, B., Bala, J. A., Hafiz, T. R., Aliyu, I. A., Kumurya, A. S., Badamasi, I. M., Saidu, H., Abbas, M. A., Kabuga, A. I., Abdullahi, A. S., et al. (2026) · Next research. · doi:10.1016/j.nexres.2026.101493
Impact of the COVID-19 pandemic on patients with primary immunodeficiency
Nijhawan, P., Sharfe, N., Dadi, H., & Vong, L. (2024) · LymphoSign Journal · doi:10.14785/lymphosign-2024-0007
Booster vaccination against the SARS-CoV-2: mechanisms and efficiency
Berns, S. A., Веремеев, А. В., Savicheva, A. A., Gorshkov, A. Y., & Drapkina, O. M. (2024) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2023-3820
Madelon, N., Buendía, G. A. R., Rodríguez, P. F., Donati, Y. R. A., Fontannaz, P., Ciancaglini, M., Adouan, W., Arsac, E., Fonta, N., Goldstein, R., et al. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.aee4776
Zornikova, K. V., Ivanova, N. O., Aleshina, O. A., Sheetikov, S. A., Davydova, V. D., & Васильевна, Б. А. (2024) · Гематология и трансфузиология · doi:10.35754/0234-5730-2024-69-2-200-216
Jo, S., Min, K., & Cho, S. (2026) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2026.108997
Ma, Y., Ye, C., Piepenbrink, M. S., Mahmoud, S. H., Čupić, A., Gracián-Castro, E., Jackson, N. D., Bayoumi, M., Padron, A. S., García‐Sastre, A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.16.682699
Lee, D. B., Kim, H., Jeong, J. H., Jang, U. S., Chang, Y. Y., Roh, S., Jeon, H., Kim, E. J., Han, S. Y., Maeng, J. Y., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.18.480994
Self-citationWeinberg, A. R., Caeg, C. O., DePalma, R., et al. (2023) · Clinical Transplantation · doi:10.1111/ctr.15072
Lu, Z., Lu, Y., Liu, D., Du, F., Wu, Q., Liao, G., Wu, Y., Zhang, R.-L., Zhou, J., & Wang, Q. (2026) · Emerging Microbes & Infections · doi:10.1080/22221751.2026.2685927 · Cited by 1
“Furthermore, clinically licensed COVID-19 mRNA vaccines, such as BNT162b2 and mRNA-1273, are administered at fixed microgram doses (30 and 100 µg per dose in adults, respectively) rather than using strict body-weight-based scaling [27, 28].”
Kelly, J. D., Leonard, S. J., Boscardin, W. J., Hoggatt, K. J., Lum, E. N., Austin, C., Byers, A. L., Tien, P. C., Bravata, D. M., & Keyhani, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-61244-7 · Cited by 1
Castellanos-Hernández, D. I., Mayoral-Chávez, M. A., Matias‐Cervantes, C. A., & Alpuche, J. J. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1752169
Stillwell, R. C. (2026) · Research Square · doi:10.21203/rs.3.rs-9962383/v1
Matsuzono, K., Mieno, M., Mashiko, T., Anan, Y., Ozawa, T., Koide, R., Tanaka, R., Kimura, A., & Fujimoto, S. (2024) · SAGE Open Medicine · doi:10.1177/20503121241272518
Main-chain disulfide-linked cationic polycarbonates for local mRNA delivery
Gong, X., Yang, Y. L., Wang, Z., Zhang, Q., & Liu, Y. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126179
Precision nanomedicine for pulmonary diseases: from molecular targeting to clinical translation
Deng, Z., Gao, W., Do, J., Aragam, S., Dawd, O., Belthur, M., Shi, D., Kalin, T. V., & Kalinichenko, V. V. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02982-0 · Cited by 2
Optimal Control of High-Risk Data Using the Convex Structured Method
Zhu, B., Qiu, D., & Xie, J. (2025) · International Journal of Fuzzy Systems · doi:10.1007/s40815-025-02038-5
Vaccination against COVID-19 in a post-pandemic era
Neto, F. L., Ceccato, A., & Ranzani, O. (2024) · European Respiratory Society eBooks · doi:10.1183/2312508x.10020223
Qiao, N., Ishikawa, J., Yasui, F., Sano, K., Miyakawa, K., Hayashi, A., Amiry, A. F., Haonan, L., Xueyang, Z., Sato, T., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.24.696305
Klinik Faz Çalışmaları Devam Eden RNA Tabanlı COVID-19 Aşı Adayları
Al, L. İ. R., Sönmezer, M. Ç., & Ünal, S. (2021) · Flora the Journal of Infectious Diseases and Clinical Microbiology · doi:10.5578/flora.20219802
Active and Passive Immunization Approaches in Transplant Recipients
Ringer, M., Azar, M. M., & Malinis, M. F. (2023) · Current Transplantation Reports · doi:10.1007/s40472-023-00406-4 · Cited by 1
Vaccination Against COVID-19 in Comorbid Patients
Ashirova, M. A., Abuova, G., & Shaimerdenova, G. (2024) · Archives of Clinical Infectious Diseases · doi:10.5812/archcid-148021
ЕГДЕ ЖАСТАҒЫ АДАМДАРДА COVID-19 ВАКЦИНАЦИЯСЫНЫҢ ТИІМДІЛІГІ
Abdusattarova, Y., ӘБЕН, Д. С., Abdolla, N., Tleulieva, R., Kali, A., & Перфильева, Ю. В. (2023) · Vestnik · doi:10.53065/j7165-0490-8708-h
Amberger, M. (2023) · Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) · doi:10.21248/gups.81592
Kim, R., Uhm, T.-G., Kim, J., Woo, D., Kim, U.-I., Meng, X. W., Yang, B., Kim, S., Kim, H.-R., Kim, J., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1571092 · Cited by 1
SARS-CoV-2 Pandemic Preventive Methods Efficacy - A Simulation Case StudyPreprint
Saad, M., & Boctor, E. M. (2021) · medRxiv · doi:10.1101/2021.10.17.21265111
Mise‐Omata, S., Ikeda, M., Takeshita, M., Uwamino, Y., Wakui, M., Arai, T., Yoshifuji, A., Murano, K., Siomi, H., Nakagawara, K., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.07.31.500554
Wang, D., Pan, Z., Jiang, L., Peng, H., He, Y., Liu, Y., Zheng, X., Ding, C., Tang, W., Zhang, C., et al. (2025) · Biosafety and Health · doi:10.1016/j.bsheal.2025.11.004 · Cited by 1
GESTÃO DE RISCOS EM SAÚDE PÚBLICA: APRENDIZADOS CRUCIAIS DE EPIDEMIAS E PANDEMIAS
Aleixo, G. H., Segundo, Á. R. D. S. S., Diniz, C. E. B., et al. (2023) · doi:10.56161/sci.ed.2023111004
Frailty in Critically Ill Patients with COVID-19: The Lessons Learned
Subramaniam, A., Ling, R. R., & Shekar, K. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-61939-7_4
Rabeau, A., Lavesque, J., Joseph, C., Cortot, A. B., & Mazières, J. (2021) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(21)00108-7 · Cited by 2
Nickel, K. B., Fraser, V. J., Babcock, H. M., & Kwon, J. H. (2022) · Antimicrobial Stewardship & Healthcare Epidemiology · doi:10.1017/ash.2022.299
COVID-19 Vaccine Survey among Healthcare Workers. A Community Experience.
Theophilus, N., Ríos‐Bedoya, C. F., & Bachuwa, G. I. (2022) · Spartan Medical Research Journal · doi:10.51894/001c.35628 · Cited by 1
SARS-CoV-2 intra-host evolution during acute infection in COVID-19 patients
Ventura, C. D., Bergna, A., Ciubotariu, C. L., et al. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1794039
“Spearman’s correlation analysis was conducted to evaluate the relationship between Ct value (Baden et al., 2020) and number of mutations.”
Google Trends Analysis of Otologic Symptom Searches Following COVID-19.
Kim, J. K., Tawk, K., Kim, J. M., Djalilian, H. R., & Abouzari, M. (2024) · PubMed Central · doi:10.22038/ijorl.2024.75617.3532
Amvrosіeva, T. V., Богуш, З. Ф., Бельская, И. В., et al. (2022) · Лабораторная диагностика Восточная Европа · doi:10.34883/pi.2022.11.4.003
In vivo reprogramming of cytotoxic effector CD8 T cells via fractalkine-conjugated mRNA-LNPs
Corrigan, A. R., Ngiow, S. F., Statzu, M., Albertus, A., Pampena, M. B., Nordin, J. M. L., Carro, S. D., Harper, J. L., Stammen, R. L., Wood, J., et al. (2026) · Science Immunology · doi:10.1126/sciimmunol.aec3436 · Cited by 6
Engineering the Future of Precision Medicine: A Comprehensive Guide to RNA Therapeutics
Athanasopoulou, K., Daneva, G. N., Michalopoulou, V.-I., Stamelou, M.-L., Tsiakanikas, P., & Adamopoulos, P. G. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48080809
An Update on the Leading COVID-19 Vaccines
Eladely, A. (2021) · The University of Louisville Journal of Respiratory Infections · doi:10.18297/jri/vol5/iss1/2
Molecular signature of COVID-19 prior to its exacerbation by multi-omics survey
Suzuki, T., Kita, Y., Yanagida, K., Maeda, K., Hashidate‐Yoshida, T., Nakanishi, H., Ohto‐Nakanishi, T., Terada-Hirashima, J., Tsujimoto, Y., Hojo, M., et al. (2026) · PLoS ONE · doi:10.1371/journal.pone.0352423
Kulikov, A. N., Muravyevа, N. V., Belov, B. S., et al. (2023) · Modern Rheumatology Journal · doi:10.14412/1996-7012-2023-6-72-78
Mogollon, J., Halaseh, G., & Swaminathan, N. (2023) · Contemporary Endocrinology · doi:10.1007/978-3-031-28536-3_1 · Cited by 1
Gong, Y., & Guo, L. (2025) · BIO Web of Conferences · doi:10.1051/bioconf/202517402006
Fuchs, T., Appelt, D., & Ellemunter, H. (2024) · Vaccines · doi:10.3390/vaccines12010098
SARS-CoV-2 spike protein in infectivity
Altaie, A. M., Hamdy, R., Husseiny, M. I., & Soliman, S. S. M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-19170-1.00015-2
Marinelli, T. M., Chaparro, C., Humar, A., & Kumar, D. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.06.007
Anderson, E. J., Jackson, L. A., Rouphael, N., Widge, A. T., Montefiori, D. C., Doria‐Rose, N. A., Suthar, M. S., Cohen, K. W., O’Connell, S. E., Makowski, M., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1594631/v1
Self-citationShe, C. H., Tsang, H. W., Yang, X., Tsao, S. S. L., Tang, C. S.-M., Chan, H. S., Kwan, M. Y. W., Chua, G. T., Yang, W., & Ip, P. (2024) · BMC Genomic Data · doi:10.1186/s12863-024-01238-6
Razak, M. K. A., Jebur, A. A. A. R., Hamdan, B. J. A., & Ibrahim, A. K. (2023) · medRxiv · doi:10.1101/2023.01.20.23284814
SARS-CoV-2 Pandemic: From Despair to Hope
Tabish, S. A. (2021) · Anaesthesia & Critical Care Medicine Journal · doi:10.23880/accmj-16000188
Cooper, D. K., Sobolik, J. S., Kovačević, J. J., Rock, C. M., Sajewski, E. T., Guest, J. L., Lopman, B. A., Jaykus, L., & León, J. S. (2022) · medRxiv · doi:10.1101/2022.04.06.22273125
Evolution of HIV virulence in response to disease-modifying vaccines: A modeling study
Reid, M. C., Mittler, J. E., Murphy, J. T., Stansfield, S. E., Goodreau, S. M., Abernethy, N. F., & Herbeck, J. T. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.08.071
Imai, K., Kitagawa, Y., Tabata, S., Matsuoka, M., Nagura‐Ikeda, M., Fukada, A., Miyoshi, K., Saito, Y., Tarumoto, N., & Maeda, T. (2021) · Research Square · doi:10.21203/rs.3.rs-560458/v1
Junkins, E. J., Chehab, S., Lee, K. M. N., & Clancy, K. B. H. (2024) · Women s Health · doi:10.1177/17455057241285189 · Cited by 1
Fung, S. S.-P. (2024) · Drugs & Therapy Perspectives · doi:10.1007/s40267-024-01124-2
Wang, X., Tian, Z., Benitez, A. P., Bian, X., Vaidya, A., Guerrero, E. D., Sun, Y., Zhang, C., Duan, Y., Wei, J., et al. (2026) · Nature Chemical Engineering · doi:10.1038/s44286-026-00425-9 · Cited by 2
Kuczkowska, K., Bjerkan, L., Stubsrud, E., Husbyn, H., Chellappa, S., Hauge, A., Skarshaug, R., Torgersen, M. L., Heim, J. B., Jørgensen, M. J., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-46223-8 · Cited by 1
Dabilgou, A. A., Ouédraogo, É., Kyelem, J. M. A., Dravé, A., Wanré, O., Napon, C., & Millogo, A. (2025) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-025-10249-8
“The side effects of the COVID-19 vaccine were reported by 30% to 90% of participants in ran - domised clinical trials of the COVID-19 vaccines (Baden et al. 2021 ; Polack et al. 2020).”
Advances in therapeutics and vaccines for Marburg virus disease: challenges and future directions
Kandi, V., Branda, F., Alissa, M., Pattnaik, G., Alhegaili, A. S., Alshehri, M. A., Sahu, A., & Mohapatra, R. K. (2026) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2026.2723576 · Cited by 1
Bergada, C. B., Song, P., Knudsen, K. B., Jaynes, C. L., Leuvenink, H. G. D., Llorente, V. R., van Furth, L. A., Hager, H., Nørregaard, R., Hillebrands, J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.28.672793
SARS-CoV-2: A Comprehensive Insight into DNA, RNA, Subunit, and Viral Vaccines
Tabassum, S. (2025) · Medical virology · doi:10.1007/978-981-95-1426-7_18
Li, J., Gong, L., Li, J., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.04.093
The effect of COVID-19 on cancer immunotherapy and cancer care
Niederhuber, J. E. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-87763-3.00022-8
Kang, H., Lee, J., Jung, J. H., & Oh, E. (2023) · Vaccines · doi:10.3390/vaccines11121803
Walmsley, S. L., Nabipoor, M., Qi, F., Lovblom, L. E., Ravindran, R., Colwill, K., & Gingras, A. (2026) · Clinical & Translational Immunology · doi:10.1002/cti2.70095 · Cited by 1
Ferreira, N. J. S., Carvalho, R. P. R., de Oliveira, B., Raimundo, V. D., Bastos, D. S. S., Tostes, H. D. A., Lopes, S. G., Machado‐Neves, M., & Silva, E. D. A. M. D. (2026) · Journal of Parasitic Diseases · doi:10.1007/s12639-025-01900-5
Sana, A., Noor, S., Iqbal, K., et al. (2024) · Journal of Toxicological Studies · doi:10.59400/jts.v2i2.1372
Al-Mozaini, M., Karim, A. R., & Islam, S. S. (2023) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2023.05.030
Copper‐Catalyzed Amino Radical Transfer‐Mediated Deborylation for Chiral Ester Synthesis
Peng, Y.-H., Ding, W., Dai, Z.-Y., et al. (2026) · Angewandte Chemie · doi:10.1002/ange.6992175
Evaluation of the United States COVID-19 Vaccine Allocation StrategyPreprint
Islam, M. R., Oraby, T. F., McCombs, A., Chowdhury, M. M., Al-Mamun, M., Tyshenko, M. G., & Kadelka, C. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3869650
Basile, K., Agius, J. E., Fong, W., McPhie, K. A., Fennel, M., Ko, D., Heuston, L., Lam, C., Arnott, A., Chen, S. C.-A., et al. (2025) · Viruses · doi:10.3390/v17091161 · Cited by 1
“These mutations are particularly frequent in the spike (S) glycoprotein, the target for many vaccines and therapeutics [1,2].”
Taymur, B. D., & Toklucu, G. (2026) · Journal of Health Sciences and Medicine · doi:10.32322/jhsm.1883733
Eosinophils protect against SARS-CoV-2 following a vaccine breakthrough infectionPreprint
Moore, K. M., Foster, S. L., Kar, M., Floyd, K. A., Elrod, E. J., Williams, M. E., Velden, J. W. V., Ellis, M. L., Malik, A. A., Wali, B., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.08.607190
Risk of SARS-CoV-2 infection and adverse outcomes among vaccinated patients with tuberculosis
Chang, R., Chen, S.-Y., Hsieh, T. Y. J., Chen, H.-Y., Wang, S., Hung, Y., & Wei, J. C.-C. (2025) · Public Health · doi:10.1016/j.puhe.2024.09.028
Deng, Z., Dunn, A. W., Sun, D. Q., & Shi, D. (2026) · Applied Physics Reviews · doi:10.1063/5.0342617 · Cited by 1
Metadata
- Authors
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and Infectious Diseases, Bethesda (D.F., M.M., J. Mascola, L.P., J.L., B.S.G.) — both in Maryland; Saint Louis University School of Medicine, St. Louis (S.F.); University of Illinois, Chicago, Chicago (R.N.); George Washington University School of Medicine and Health Sciences, Washington, DC (D.D.); University of California, San Diego, San Diego (S.A.S.); Vanderbilt University School of Medicine, Nashville (C.B.C.); Quality of Life Medical and Research Center, Tucson, AZ (J. McGettigan); Johnson County Clin-Tr...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-04
- Volume
- 384
- Issue
- 5
- Pages
- 403-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787219
- OpenAlex
- W3113734454
- Cited by
- 10,119
- References
- 24
- Citations by year
- 2026: 622 · 2025: 962 · 2024: 1186 · 2023: 1691 · 2022: 2854 · 2021: 2793
- FWCI
- 240.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (ACTG Leadership and Operations Center UM1 AI 68636, HPTN Leadership and Operations Center UM1 AI 68619, HVTN Laboratory Center UM1 AI 68618, HVTN Leadership and Operations Center UM1 AI 68614, HVTN Statistics and Data Management Center UM1 AI, IDCRC leadership group 5 UM1 AI148684-03)
- Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No. 75A50120C00034)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, vaccine safety, reactogenicity, adverse events, vulnerable populations, older adults, immunocompromised patients, breakthrough infection, severe COVID-19 prevention
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult, Patient Acuity, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.